New UK Investment Facility To Boost Horizon-Scanning For Pipeline Drugs
An updated UK PharmaScan platform is to be delivered within the first three years of the new voluntary drug pricing scheme, with companies agreeing to provide “timely, accurate and comprehensive information” for all their medicines in development.
You may also be interested in...
Under the UK’s newly published voluntary pricing and access scheme, stakeholders will be more easily able to track a new product’s journey from the development pipeline to licensing and on to commissioning by the National Health Service. A close eye will also be kept on any access problems caused by variations in the implementation of HTA guidance.
NHS England has committed to two pilots on innovative pricing models for advanced therapies under the UK’s new voluntary pricing agreement for new medicines.
The VPAG includes a gradual rise in allowable branded medicine sales to the NHS and differentiated payment mechanisms for older and newer products. Industry will also commit to invest £400m in “pioneering” clinical trials, innovative manufacturing, and novel approaches to health technology assessments.